News

TG Therapeutics Reports Impressive Growth and 2025 Outlook

TG Therapeutics Reports Impressive Growth and 2025 Outlook

TG Therapeutics Celebrates Milestones and Looks to the Future

In a significant announcement, TG Therapeutics, Inc. (TGTX) has shared its financial results for the fourth quarter and the entire year of 2024, highlighted by impressive revenue figures and ambitious targets for 2025. The company's net revenue for their flagship product, BRIUMVI, reached $103.6 million for the fourth quarter and totaled $310 million for the full year, reflecting remarkable growth.

Performance Breakdown for 2024

Michael S. Weiss, the Chairman and CEO of TG Therapeutics, expressed pride in the company’s performance, emphasizing the robust adoption of BRIUMVI by patients with relapsing forms of multiple sclerosis (MS). In addition, he noted enhancements in their patent portfolio through to 2042 and the initiation of new clinical trials, which includes testing for subcutaneous configurations of BRIUMVI.

Key Highlights of 2024

  • BRIUMVI generated an impressive U.S. net product revenue of $103.6 million in the fourth quarter and $310 million for the full year of 2024, marking an annual growth of approximately 250%.
  • The company secured three new patents for BRIUMVI, ensuring protection through 2042.
  • In partnership with Neuraxpharm, BRIUMVI has officially launched in Europe, broadening its reach in the market.

Research and Development Advancements

TG Therapeutics is not only focused on revenue growth but also on advancing its research and development. The company has initiated several studies showcasing the efficacy and safety of BRIUMVI in chronic diseases.

Presentation of Data

  • The company presented five-year data from its ongoing studies, indicating that 92% of patients treated with BRIUMVI maintained functional stability with minimal relapses.
  • In the ENHANCE trial, rapid infusions of BRIUMVI were well-tolerated, demonstrating the treatment's significance in clinical practice.

Pipeline and Future Plans for Growth

As part of its growth strategy, TG Therapeutics has outlined specific milestones for 2025, aiming for a total global revenue of approximately $540 million. This plan includes substantial investments in clinical trials and expanding its product offerings.

2025 Projections

  • The target for U.S. net product revenue for BRIUMVI is projected to be around $525 million for 2025.
  • Operational expenses are expected to be approximately $300 million, excluding non-cash items.
  • To enhance patient experience, pivotal programs focusing on subcutaneous formulations of ublituximab will commence.

Financial Overview for 2024

The company's fiscal health appears robust, reflecting significant improvements compared to the previous year. Gross product revenue constituted a large portion of the company’s earnings, demonstrating successful product commercialization.

Key Financial Figures

  • The total revenue for 2024 saw a substantial climb, showcasing the effectiveness of TG Therapeutics' marketing and distribution strategies.
  • Research and development costs amounted to around $94.3 million for the year, indicative of the company's commitment to innovation in therapies for B-cell diseases.
  • Net income for the full year of 2024 stood at approximately $23.4 million, a notable turnaround compared to a loss in the prior year.

Conclusion: A Promising Future for TG Therapeutics

As TG Therapeutics continues to build on its success with BRIUMVI and expands its pipeline, the outlook for 2025 and beyond appears highly promising. With a focus on research innovation and strategic partnerships, the company is well-positioned to address unmet needs in the treatment of various autoimmune disorders.

Frequently Asked Questions

What is BRIUMVI and its primary use?

BRIUMVI (ublituximab-xiiy) is a monoclonal antibody used to treat adults with relapsing forms of multiple sclerosis, aimed at reducing disability progression.

What were TG Therapeutics' revenue figures for 2024?

The company reported U.S. net revenue of $103.6 million in Q4 2024 and $310 million for the full year, representing substantial growth.

What are the company’s financial targets for 2025?

TG Therapeutics aims for a total global revenue of approximately $540 million, with a specific target of $525 million from BRIUMVI sales in the U.S.

How does TG Therapeutics plan to enhance its product offerings?

The company plans to launch pivotal programs for subcutaneous formulations of ublituximab and expand its clinical development efforts.

What developments did TG Therapeutics achieve in 2024?

The company secured additional patents for BRIUMVI, expanded its European market presence, and presented significant clinical trial data supporting the effectiveness of its therapies.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

FSS Unveils AI Tool to Simplify Bankruptcy Cases

Updated Category News Views 5

AI Revolution in Bankruptcy Management Alright, folks, there's a fresh breeze blowing in the bankruptcy management world, and it bears the acronym FSS. Financial Software Solutions is rolling out its innovative FSS Intelligence Engine. This little powerhouse aims to turn what used to be a gut-wrenching slog through mountains of paperwork into a slick, automated process....

Continue Reading
Local Expertise in Real Estate: Key to Success?

Updated Category News Views 4

Local Market Know-How: A Seller's Best Asset So you're thinking about selling your home in North Carolina, huh? Here's a tip—get yourself a local real estate pro who knows the ins and outs of your neighborhood like the back of their hand. Michael McCollum, a prominent voice from Reidsville, NC, highlights how crucial local expertise can be in navigating the widely...

Continue Reading
Crucial Insights for South GA Home Insurance Choices

Updated Category News Views 5

Understanding the Insurance Jargon Here we go again, dealing with insurance gobbledygook that’s about as clear as mud to most of us. Homeowners in South Georgia are being urged to pay attention to the differences between replacement cost and actual cash value in their insurance policies. This ain't just legalese, folks—it's your protection when disaster strikes in our...

Continue Reading
Vortex Expands UK Reach with Torrent Acquisition Boost

Updated Category News Views 5

Vortex's Ambitious UK Expansion A seasoned investor keen on infrastructure plays would find Vortex Companies’ latest move significant—not just another acquisition, but a realigned strategy for dominance as Britain braces for an infrastructure overhaul. With Torrent Drainage Services in their pocket, the Vortex Group plans to amp up its trenchless rehabilitation...

Continue Reading
University of Phoenix Grads Shine in Job Readiness

Updated Category News Views 6

University of Phoenix Graduates Proving Their Worth Dive straight into the world of University of Phoenix grads, and you're looking at some folks who seem to have the workplace game figured out. A fresh Harris Poll, done on behalf of the University itself, paints a rosy picture of these graduates from the eyes of those who actually supervise them. Turns out, managers are...

Continue Reading
EPR Fireworks, Schedule2.IT Enhance EMS Integration

Updated Category News Views 6

Joining Forces for Effective EMS Management In a move that could shake up emergency medical services, EPR Fireworks has teamed up with Schedule2.IT to amp up integration. This Florida-based partnership is all about breaking down those bureaucratic firewalls between patient care and controlled substances tracking. They’re pushing for a seamless workflow, where crucial...

Continue Reading
JennAir and Cosentino Introduce Seamless Kitchen Aesthetics

Updated Category News Views 6

It's not every day that the kitchen landscape gets a bold makeover, but JennAir and Cosentino seem to think it's time. Introducing their latest splash, the JennAir x Dekton panel collection is here to redefine what luxury kitchens can look like—an embodiment of seamless beauty that’s more sculpture than cooking space. Elevating Kitchen Design So, what's the buzz about...

Continue Reading
Medicare Payment Proposal Faces Doctor Backlash in D.C.

Updated Category News Views 4

Why Same-Day Medicare Care Matters Imagine you're gasping for breath, struggling to find relief, and then being told to wait weeks for care. It's not just an inconvenience; it's a health hazard. This isn't some arbitrary tale—it's the gritty reality for folks relying on same-day care. A group of docs and advocates recently stormed Capitol Hill sounding the alarm about a...

Continue Reading
Superga and Pasqua's Unlikely Fashion-Vineyard Fusion

Updated Category News Views 7

Superga and Pasqua: A Fusion of Fashion and Vineyards Here's one for the books: Superga, the storied Italian footwear maestro, teaming up with Pasqua Wines, straight out of Verona’s vineyard heartland. On the surface, it seems a rather odd coupling. One's got rubber soles; the other’s got corks. But they’ve pulled off a daring bedroom switch, creating a...

Continue Reading
OSHA and NSC Forge Alliance to Prevent Worksite Tragedies

Updated Category News Views 4

Forging Ahead With a Crucial Collaboration Ins, outs, ups, and downs—safety shouldn’t get lost in the shuffle, but it does. In steps the National Serious Injury and Fatality Prevention Alliance, a fresh partnership convened by OSHA with the National Safety Council—hop on board or get left behind mindsets. We’re talking about real, heads-down, hard-hitting actions...

Continue Reading

Top 5 Most Recently Viewed Articles

Empowering the Future of Open Source: ASF's New Initiatives

Updated Category News Views 191

Enhancing Open Source: The Apache Software Foundation's Commitment The Apache Software Foundation (ASF), recognized as a cornerstone of the open source community, has recently introduced innovative tools and programs aimed at strengthening and supporting global contributors. In its latest report, the ASF provides insightful statistics and highlights from the fiscal year...

Continue Reading
Verve Therapeutics Faces Class Action Lawsuit: What Investors Should Know

Updated Category News Views 74

Overview of the Class Action Lawsuit Against Verve Therapeutics Levi & Korsinsky, LLP is reaching out to investors in Verve Therapeutics, Inc. about a significant class action securities lawsuit that has major implications for shareholders. Verve Therapeutics, which is known for its groundbreaking work in gene editing, is currently facing serious allegations that could...

Continue Reading
Omada's Riverty Deal: Identity Governance Game Changer?

Updated Category News Views 181

So here’s the lowdown—Omada A/S just snagged a deal with Riverty Group on Feb 17, 2026. You know what that means? The fintech world just hit refresh. This is big news for Omada, a player in the Identity Governance and Administration (IGA) sector, which basically runs the digital bouncer business by controlling who gets in where. Riverty’s no slouch either; they’re...

Continue Reading
Hamilton Lane Expands Investment Opportunities with New Fund

Updated Category News Views 319

Hamilton Lane Introduces New Investment Fund In an exciting development for investors, Hamilton Lane, recognized as a leader in the private markets investment sector, has launched the Hamilton Lane Private Secondary Fund. This new offering builds upon the firm's extensive 24 years of expertise in secondary market investments. The firm aims to capitalize on long-term...

Continue Reading
Stetson University Celebrated for Distinction in Education

Updated Category News Views 280

Stetson University Recognized Nationally Stetson University has achieved a remarkable accolade by being named a national College of Distinction for three consecutive years. This recognition highlights Stetson's exceptional programs in various categories, notably in Business, Career Development, and support for international students. What Sets Colleges of Distinction...

Continue Reading